ResultsIQ

ResultsIQ › Latest results › GPT Healthcare Limited

GPT Healthcare Limited Q1 FY27 results deck summary

NSE: GPTHEALTH · BSE: 544131

Results deck of 3 Aug 2026, summarised by AI from the filing.

Management targets over 1,000 beds over the next two years and network occupancy around 70%.

Key takeaways

  1. Guidance Management targets over 1,000 beds over the next two years and network occupancy around 70%.
  2. Change EBITDA margin improved to 20.4% in Q1 FY27 from 17.4% in Q1 FY26.
  3. Driver ARPOB rose to ₹42,350 on improved clinical mix and operating efficiencies.

Original filing on BSE

GPT Healthcare Limited Q1 FY27 results

As filed: Revenue ₹126 cr (+18% year on year), EBITDA ₹24.2 cr (+42% year on year), PAT ₹12.7 cr (+59% year on year), EBITDA margin 19.2% (+326 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹126 cr (+25% year on year), EBITDA ₹23.4 cr (+17% year on year), PAT ₹14.6 cr (+12% year on year), EBITDA margin 18.5% (−132 bps). Score 82 of 100, Above trend. Revenue and EBITDA growth were well above the company's own trend; profit growth was above it. EBITDA margin fell 132 bps year on year. Tax rate 8%. Share price after the results: +4.4% in 30 days (Nifty 500: +2.9%).
  • Q3 FY26: Revenue ₹120 cr (+18% year on year), EBITDA ₹20.7 cr (−6% year on year), PAT ₹9.4 cr (−22% year on year), EBITDA margin 17.2% (−433 bps). Score 47 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA growth was below it; profit growth was well below it. EBITDA margin fell 433 bps year on year. Profit fell 15% from last quarter. Share price after the results: −5.7% in 30 days (Nifty 500: −1.9%).
  • Q2 FY26: Revenue ₹119 cr (+12% year on year), EBITDA ₹23.0 cr (−4% year on year), PAT ₹11.0 cr (−27% year on year), EBITDA margin 19.3% (−331 bps). Score 30 of 100, Below trend. EBITDA margin fell 331 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −5.4% in 30 days (Nifty 500: 0.0%).
  • Q1 FY26: Revenue ₹107 cr (+9% year on year), EBITDA ₹17.0 cr (−11% year on year), PAT ₹8.0 cr (−20% year on year), EBITDA margin 15.9% (−350 bps). Score 27 of 100, Below trend. EBITDA margin fell 350 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 38% from last quarter. Share price after the results: −13.8% in 30 days (Nifty 500: +0.7%).
  • Q4 FY25: Revenue ₹101 cr (+2% year on year), EBITDA ₹20.0 cr (−13% year on year), PAT ₹13.0 cr (0% year on year), EBITDA margin 19.8% (−343 bps). Score 24 of 100, Below trend. EBITDA margin fell 343 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −7.6% in 28 days (Nifty 500: +1.1%).
  • Q3 FY25: Revenue ₹102 cr (+5% year on year), EBITDA ₹22.0 cr (0% year on year), PAT ₹12.0 cr (+9% year on year), EBITDA margin 21.6% (−111 bps). Score 36 of 100, Below trend. EBITDA margin fell 111 bps year on year. Not enough history for a trend yet: scored on growth alone. Revenue fell 4% from last quarter.
  • Q2 FY25: Revenue ₹106 cr, EBITDA ₹24.0 cr, PAT ₹15.0 cr, EBITDA margin 22.6%. Not scored. No result for the same quarter last year.

Past price moves after results do not indicate future moves. Not a recommendation.

GPT Healthcare Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.